Unlike the last few weeks, 'vaccine Monday' has become 'vaccine Tuesday', as the Britain's "V-Day" vaccinations grabbed headlines earlier, and now the country's most promising project - the AstraZeneca-Oxford jab - has published peer-reviewed data in the Lancet purporting to show that the shot is safe and effective. However, many questions about its efficacy and safety remain, and if anything, the data suggests that more research on the jab is needed.

Despite this, researchers confirmed they will now submit their data to regulators for approval to deploy the vaccine in mass immunization campaigns across the UK, Brazil, India and countries in Europe, among other places.

Still, the peer-reviewed study, which can be found here, declared that the vaccine "has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19".

Data also showed there were four case of Bell's Palsy among the vaccine group (that's a condition characterized by facial paralysis).

Just out @TheLancet: @AstraZeneca @UniofOxford vaccine interim trial results
—Higher efficacy w/ low dose looks real, not likely statistical
—1 case of transverse myelitis troubling
—Transmission suppressed👇https://t.co/k5esfui2h6 pic.twitter.com/QC1s1nMpFf

— Eric Topol (@EricTopol) December 8, 2020

What's more, the data published Tuesday showed the study didn't involve even a single volunteer above the age of 55. It also left questions about the illnesses that let to trial halts around the world earlier this year unexplained.

What's more, unlike Moderna and Pfizer, the AstraZeneca vaccine (which uses a different method) was found to be just 62% effective for all volunteers who received two doses.

The news follows a detailed report on the Pfizer vaccine released by the FDA.

Of course, not everybody sees the lower efficacy numbers as a bad thing.

Read the full report below: